Skip to content

Pharminent

cropped-ChatGPT-Image-May-28-2026-10_46_23-PM.png
Primary Menu
  • Home
  • Signal News
  • Biopharma Brief
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Regulatory Interactive Calendar
    • Manufacturing Intelligence
  • Contact
Light/Dark Button
Brief
  • Home
  • Regulatory
  • FDA turns to old drugs to address new diseases, persistent medical needs
  • Regulatory

FDA turns to old drugs to address new diseases, persistent medical needs

BioSpace

The FDA is looking to retool drugs with sufficient evidence to support their use in other indications, particularly those with unmet need.

Read full story

pharminent May 12, 2026 (Last updated: May 16, 2026)

BioSpace

The FDA is looking to retool drugs with sufficient evidence to support their use in other indications, particularly those with unmet need.

Read full story

Sign up to receive free daily digest

Check your inbox or spam folder to confirm your subscription.

Post navigation

Previous: Novo says high-dose Wegovy can cause 28% weight loss
Next: BridgeBio stands up to Pfizer in ATTR-CM as late-stage data hint at better survival

Related Stories

  • Regulatory

FDA Issues Draft Guidance to Help Accelerate Cell and Gene Therapies for Patients

pharminent June 2, 2026
  • Regulatory

FDA approves AstraZeneca’s Imfinzi-BCG combination for NMIBC therapy

pharminent June 1, 2026
  • Regulatory

Replimune gives cancer immunotherapy a third try after FDA leadership shakeup

pharminent May 29, 2026

You May Have Missed

  • Policy / Pricing

Eli Lilly issues data sharing ultimatum to 340B hospitals

pharminent June 2, 2026
  • M&A / Deals

Fulcrum exploring a potential sale after FDA sidelined its sickle cell drug

pharminent June 2, 2026
  • Clinical Data

ASCO 2026: Kelonia presents positive in vivo CAR-T data in multiple myeloma

pharminent June 2, 2026
  • Clinical Data

ASCO26: In vivo oncology approaches continue to show promise

pharminent June 2, 2026
Copyright © 2026 All rights reserved. | ReviewNews by AF themes.